This product may be covered by your insurance or Medicare Part D. Check now or call us at 877-840-8218
Learn More About Omnipod 5
Insulet Omnipod® 5
The Omnipod® 5 Automated Insulin Delivery System picks up where Insulet’s highly successful Omnipod DASH Insulin Management System left off. Both of these systems rely on a tubeless and waterproof* Pod to deliver insulin continuously for up to three days. But only the Omnipod 5 system is totally automated and designed for use along with the Dexcom G6 Continuous Glucose Monitor System, allowing you to avoid highs and lows more effectively than ever.†
The system includes three basic components. These are the Pod, a compatible smartphone‡ (or a specialized controller, offered free of charge), and the Dexcom G6 system (sold separately).
This product may be covered by your insurance. Check now or call us at 877-840-8218.
- SmartAdjust™ technology adjusts your insulin delivery rate every five minutes
- Activity mode temporarily reduces insulin levels during workouts
- SmartBolus bolus calculator takes your CGM data and trends into account
- Tubeless, waterproof* Pods - just like those used in the Omnipod DASH system
- Avoid the need for multiple insulin injections each day
- Controllable with a smartphone app‡ or the Omnipod 5 Controller
Frequently Asked Questions - Omnipod 5
The Omnipod 5 system is Insulet’s newest insulin delivery system. It is largely similar to Insulet’s previous system, the Omnipod DASH Insulin Management System. However, the updated system includes Dexcom G6 compatibility and several other added features.
Your insurance may cover the cost of purchasing the Omnipod 5 system. Get in touch with our team of diabetes product experts to learn more.
As of April 2022, the FDA has only approved the Omnipod 5 system for use by people with type 1 diabetes. That may change in the future, as Insulet has released the results of a feasibility study on using this product with type 2 diabetes.
The Omnipod 5 does not have continuous glucose monitoring capabilities on its own. However, the system can wirelessly communicate with the Dexcom G6 CGM System.
Per the FDA, the Omnipod 5 system is approved for use in people 2 or older who have also been diagnosed with diabetes type 1.
The Omnipod 5 system communicates with the Dexcom G6 CGM. Through the SmartAdjust technology that is built into the Pod, the pump can automatically increase, decrease and pause delivery of insulin based on current and predicted glucose values from the CGM. The Omnipod 5 SmartBolus calculator is the software that can calculate a suggested bolus dose based on the carbohydrates entered by the user, most recent sensor glucose value, insulin on board (IOB), correction factor, insulin to carbohydrate ratio, and the target glucose value.
Yes! This integration is the first of its kind and studies show that using this automated insulin delivery (AID) system (1,2) increases glucose time in range for children and adults with type 1 diabetes(5,6) by 11%.** Also patients using the AID systems saw reduced hypoglycemic range by 2%. Both of these factors could leads to better overall health for those living with type 1 diabetes.
**Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO 2. Section of Pediatric Endocrinology, Yale SChool of Medicine, New Haven, CT: 3 Section of Pediatric Diabetes and Endocrinology, Stanford School of Medicine, Palo Alto, CA; 5 Upstate Medical University, Syracuse, NY; 6. Division of Endocrinology, Center for Diabetes Technology, University of Virginia, Charlottesville, VA; Insulet Corp, Acton, MA
Yes, US MED® accepts Medicare nationwide. The Omnipod 5 falls under prescriptions and coverage is a part of Medicare Part D*. If you meet the requirements of glucose self-testing 4 times per day, or using a CGM, or already wearing an insulin pump, then Medicare will cover 80% of your out-of-pocket costs*, after the deductible is met.
*The Pod has an IP28 rating for up to 25 feet for 60 minutes. The controller is not waterproof.
†Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (70-180mg/dL) in adults/adolescents and children as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001; ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001, respectively. Mean time > 180 mg/dL (12AM-6AM) as in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.1% vs. 20.7%; 42.2% vs. 20.7%, P<0.0001, respectively. Mean time >180 mg/dL (6AM -12AM) in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.6% vs. 26.1%; 46.4% vs. 33.4%, P<0.0001, respectively. Median time in <70 mg/dL (12AM-6AM) in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.07% vs. 0.82%,P<0.0001; 0.78% vs. 0.78%, P=0.0456, respectively. Median time <70 mg/dL (6AM-12AM) in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 1.91% vs. 1.08%, P<0.0001; 1.17% vs. 1.62%, P=0.2545, respectively. Results measured by CGM.
‡For a list of compatible smartphone devices visit omnipod.com/compatibility.
, , ,
, , ,
, , ,
US Med® Patient?
If you're an existing patient, the easiest way to manage your account is by logging into the patient portal.
Interested in Becoming a US MED® Patient?
It's simple, fast and easy! Just complete a quick form or call 1-877-840-8218 now and let us take care of the rest.